Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Oct

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Welcome and Introduction to Vi3C

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Verifying the Seen and Unseen by AI in Cancer Imaging

AI-Extracted Chart Data for Expanding Surgical Oncology Learnings

Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families

Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas

Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights